Pacific Biosciences of California, Inc.

PACB
Precision medicineHealthcare diagnosticsGenomic analysis
$1.30vs prev close-0.05(-3.71%)
$1.0752W Range$2.73
14% from low
-0.07 (-5.15%)Past 1M
Price
ARK Trade PatternPREMIUM
1M Trades
-
No trades in 1M
1M net buy
$0
0 shares
Portfolio Weight
0.25%
1M -0.04%p
Holding ETFs
2 ETFs
ARKG · ARKK

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -2.8% · Market value -23.9% · Weight -0.04%p

Trade Intensity
No trades in 1M
Trade Log
DateActionETFSharesCloseEst. total
26.06.15SELLARKK191,794$1.32$253.2K
26.06.12SELLARKK12,912$1.31$16.9K
26.06.11SELLARKK392,952$1.35$530.5K
26.06.10SELLARKK224,182$1.37$307.1K
25.12.30BUYARKG · ARKK423,426$1.73$732.5K
25.12.23BUYARKG · ARKK333,370$1.82$606.7K
25.12.22BUYARKG · ARKK798,771$1.82$1.5M
25.11.20BUYARKG · ARKK290,617$1.88$546.4K
25.11.06BUYARKG · ARKK252,561$1.78$449.6K
25.10.30BUYARKK633,420$1.94$1.2M
25.10.29BUYARKK1,028,318$2.01$2.1M
25.10.28BUYARKK214,038$1.97$421.7K
25.10.27BUYARKK562,505$2.09$1.2M
25.10.24BUYARKK1,353,313$2.02$2.7M
25.10.23BUYARKK1,035,568$1.95$2.0M
06.15SELL
191,794
ARKKClose$1.32Est. total$253.2K
06.12SELL
12,912
ARKKClose$1.31Est. total$16.9K
06.11SELL
392,952
ARKKClose$1.35Est. total$530.5K
06.10SELL
224,182
ARKKClose$1.37Est. total$307.1K
12.30BUY
423,426
ARKG · ARKKClose$1.73Est. total$732.5K
12.23BUY
333,370
ARKG · ARKKClose$1.82Est. total$606.7K
12.22BUY
798,771
ARKG · ARKKClose$1.82Est. total$1.5M
11.20BUY
290,617
ARKG · ARKKClose$1.88Est. total$546.4K
11.06BUY
252,561
ARKG · ARKKClose$1.78Est. total$449.6K
10.30BUY
633,420
ARKKClose$1.94Est. total$1.2M
10.29BUY
1,028,318
ARKKClose$2.01Est. total$2.1M
10.28BUY
214,038
ARKKClose$1.97Est. total$421.7K
10.27BUY
562,505
ARKKClose$2.09Est. total$1.2M
10.24BUY
1,353,313
ARKKClose$2.02Est. total$2.7M
10.23BUY
1,035,568
ARKKClose$1.95Est. total$2.0M
1 / 8

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline
Institutional Holders
1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest
LIVE
Shares
23,397,905
Portfolio Weight
0.25%
in ETF 0.83%
Est. Value
$30M
30D Net
$0

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Analyst recommendation distribution7
Overall Opinion
Buy
Buy
4
Hold
2
Strong Sell
1
Analyst Targets
avg.
$2.29
vs Current +69.8% upside
Current$1.35
Low ~ High$1.25 ~ $3.00
Firm
Position
Price Target
Upside / Downside
Close Price
Action
Date
Barclays
Underweight
$1.50
+11.11%
Maintain
2026-05-11
Barclays
Underweight
$1.00
-25.93%
Maintain
2026-04-14
Barclays
Underweight
$1.50
+11.11%
Downgrade
2026-03-06
Barclays
Equal-Weight
$2.00
+48.15%
Maintain
2025-12-15
Piper Sandler
Neutral
$2.00
+48.15%
Maintain
2025-11-11
1 / 4
Avg Target
$2.29
vs Current +69.8% upside
Buy
7 analysts
Buy 4Hold 2Strong Sell 1
Low $1.25
Current $1.35
High $3.00
FirmPositionTargetUpsideCloseActionDate
BarclaysUnderweight$1.50+11.11%Maintain26.05.11
BarclaysUnderweight$1.00-25.93%Maintain26.04.14
BarclaysUnderweight$1.50+11.11%Downgrade26.03.06
BarclaysEqual-Weight$2.00+48.15%Maintain25.12.15
Piper SandlerNeutral$2.00+48.15%Maintain25.11.11
1 / 4

Price Information

Previous Close$1.35
Open$1.24
Day Range$1.22 - $1.38
52-Week Range$1.07 - $2.73
1-Year Change2.27%

Trading Volume

Volume7,070,102
Avg Volume (3mo)6,568,359

Valuation

Market Cap419.6M
Book Value$-0.11
Shares Outstanding310,830,759

Financials

Revenue (TTM)159.3M
Net Income-131,387,000
EPS$-0.42
EBITDA199.2M

Profitability

P/E Ratio-
P/B Ratio-12.62
Return on Equity (ROE)-929.32%
Return on Assets (ROA)-14.07%
Profit Margin-82.49%
EV/EBITDA4.48
Beta2.32

Dividend

Dividend Rate-
Dividend Yield-

Technical

RSI(14)45.88
Company Overview

Pacific Biosciences of California (PACB) designs, develops, and manufactures advanced sequencing solutions, primarily their SMRT technology and instruments like Revio and Sequel, to address complex genetic challenges. They offer a comprehensive suite of systems, consumables, and reagent kits for various applications. PACB serves a broad range of research and clinical institutions, including pharmaceutical, agricultural, and public health organizations, positioning itself as a key player in the genomics field.

P/B
-12.62
Negative equity
ROE
-929.3%
Persistent loss
Beta
2.32
Extreme volatility
RSI(14)
45.9
Neutral

AI-generated summary. Not investment advice.

Recent News

Mymoneywood cross-analyzes and curates publicly available SEC 13F-HR filing data. We do not provide investment advice and do not recommend buying or selling any specific securities.

Past performance does not guarantee future results. All investment decisions and responsibilities rest with the user.

Terms of Service·Investment Disclaimer·Privacy Policy·Refund Policy

Always summer | biz@mymoneywood.com
© 2026 Always summer. All rights reserved.

Enter your email below to sign up for the newsletter.

By entering your email you agree to our Privacy Policy. You can unsubscribe anytime.